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Abstract: Host genetic factors are crucial risk determinants for many human cancers. In this framework, an interesting model is 
represented by prostate cancer (PC), which is featured by a complex pathophysiology with a strong genetic component. Multiple genes 
seem to influence PC risk and several single nucleotide polymorphisms (SNPs) of candidate genes modifying PC susceptibility have been 
identified. It is noteworthy the potential association of common SNPs in pro-inflammatory genes with PC risk, since chronic 
inflammation is assumed to play a key role in prostate carcinogenesis. With the aim to identify candidate genes as an experimental basis 
to develop new strategies for both prevention and treatment of PC, we have investigated the potential role of common SNPs of a gene 
cluster (TLR4, TLR2, PTGS2 and 5-Lo), involved in innate and inflammatory response, in PC cases, age-matched controls and 
centenarians from Sicily. Six SNPs were genotyped and their association with PC risk determined. Statistical analysis evidenced a 
significant association of some pro-inflammatory gene SNPs with an increased risk of PC. Furthermore, significant differences were 
observed comparing the three groups in the combined presence of a “high responder” pro-inflammatory profile. Overall, the present 
results suggest the likely association of these SNPs and PC risk, clearly motivating the need of larger studies to confirm the role of these 
genes in PC development and/or progression.  
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INTRODUCTION 
 Host genetic factors may play a critical role in the patho-
physiology of many human cancers [1]. An interesting model is 
prostate cancer (PC), which represents the second principal cause of 
cancer-related deaths in Western males. It is likely that prostate 
cancers can take decades to progress to a clinically manifest 
disease, making their diagnosis and treatment difficult [2,3]. Over 
the last two decades, serum prostate-specific antigen (PSA) has 
been considered a valuable tool for PC surveillance. However, the 
age-adjusted mortality rates of PC have remained fairly constant. At 
the present, there is an overall consensus to consider PSA a 
nonspecific marker to diagnose PC. Increased serum levels of PSA 
have frequently been observed in several other disease states of the 
prostate gland than cancer [4-6]. On the other hand, different 
biomarkers of various stages of PC development have recently been 
identified as promising tools for PC diagnosis [5,7,8].  
 Currently, the evidence for a strong genetic background in PC 
development is compelling. Several case-control studies, twin 
studies, and segregation analyses have consistently found genetic 
susceptibility to PC and its clinical outcome [6,9-11]. Several 
candidate genes of PC risk have been identified and their 
interaction, either additively or epistatically, has been hypothesized. 
Furthermore, common single nucleotide polymorphisms (SNPs) of 
a series of low penetrance alleles, referred to as “genetic modifier 
alleles”, are likely to play an important role in PC susceptibility. 
The list of these variants is long and the major pathways under 
examination include those involved in androgen action, DNA 
repair, carcinogen metabolism and inflammation [6]. There is also a 
general consensus that specific combinations of these variants, in 
the appropriate environmental settings, have the potential to 
profoundly affect the risk of PC development.  
 In the present study, we have assessed the potential role of 
some common SNPs of the Toll-Like Receptor (TLR)-4,-2, cyclo- 
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oxygenase-(COX)-2 (described as PTGS2), and 5-lipoxygenase (5-
Lo) genes, all encoding molecules involved in innate immunity and 
inflammatory response, in PC development. Genetic variants of 
these genes, mostly SNPs, determine pro-inflammatory genotypes 
known to modulate and increase risk of chronic inflammatory states 
and tissue damage and to create a tissue milieu favoring carcino-
genesis, there by promoting development and progression of PC. In 
this study, we have compared selected SNPs in PC patients, in 
healthy controls, and in a second control group of centenarians, 
“exceptional individuals”, who have been able to escape major 
common age-related diseases, including cancer [12-14]. The results 
of this study could help understand the pathophysiology of PC, 
further clarifying the association between the genetics of 
inflammation and PC susceptibility. In addition, they could allow 
the definition of a PC high risk profile, eventually leading to both 
early recognition of individuals at risk of disease and identification 
of potential molecular targets for prevention and/or treatment. 
SUBJECTS AND METHODS 
Patients and Controls  
 The study included 50 Sicilian patients with PC at the time of 
their admission to the Department of Oncology of Palermo 
ARNAS-Civico Hospital (age range 60–80 years). Controls were 
125 age-matched male Sicilians in good health according to their 
clinical history and blood tests (complete blood cell count, 
erythrocyte sedimentation rate, glucose, urea nitrogen, creatinine, 
electrolytes, C reactive protein, liver function tests, iron, proteins). 
A second control group consisted of 55 male centenarians (>99 
years), whose age was confirmed from records at the city hall 
and/or church registries. No cancer or other age-related diseases 
were clinically detectable in the centenarians, although some had 
reduced auditory and visual acuity. Because immigration and 
intermarriage
 
have historically been rare in the last hundred years, 
the ethnicity of all participants
 
was established by all four 
grandparents having been born in
 
Sicily. The study received 
approval from local ethic committees and all participants gave their 
informed consent. 
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Genotyping 
 The study material consisted of DNA samples. The DNA 
samples of cancer cases were obtained by prostate tissue placed into 
a suitable volume of RNA-later (RNA Stabilization Reagent, 
Applied Biosystems, California, U.S.A.), used to purify genomic 
DNA and total RNA simultaneously from each single biological 
sample with All-Prep DNA/RNA Mini Kit (Qiagen, Dusseldorf, 
Germany). Tumor samples were genotyped for SNPs of the genes 
selected in this study. In particular, six SNPs, located in the 
promoter and coding regions of TLR-4,-2, PTGS2, 5-Lo genes, 
were analysed (Table 1).  
Table 1. Genes (Accession Number), SNPs (Accession 
Number), and Substitutions Investigated in the Study  
Genes SNPs 
TLR4 (NM-138554.1) +896A/G (Asp299Gly; rs4986790) 
+1196C/T (Thr399Ile; rs4986791) 
TLR2 (NM 003264) +2408 G/A (Arg753Gln; rs5743708) 
+2029C/T (Arg677Trp; no rs available 
designation) 
PTGS2 (NM-000963) 
(Cox-2 gene)  
-765G/C (rs20417) 
5-Lo (NM000698) -1708 G/A (no rs available designation) 
 
 The DNA samples of the two control groups had been 
previously extracted from blood samples and genotyped for the six 
SNPs. The procedure for detecting the +896A/G and +1196C/T 
TLR4 and +2408 G/A and +2029C/T TLR2 SNPs (Table 1) was 
based on Restriction Fragment Length Polymorphism-PCR (RFLP-
PCR), restriction cleavage with Nco I, Hinf I, Mwo I and Mps I 
respectively (New England Biolabs, USA), and separation of DNA 
fragments by electrophoresis, as previously described [15,16]. The 
genotyping of -765G/C PTGS2 SNP was performed using RFLP-
PCR and with Aci I (New England Biolabs, USA) restriction 
enzyme, as previously reported [17]. An allele refractory mutation 
system (ARMS)-PCR was utilised to determine the -1708 G/A 5-Lo 
SNP, as previously described [17].  
Statistics 
 Allelic and genotypic frequencies were evaluated by gene 
count. The data were tested for the goodness of fit between the 
observed and expected genotype frequencies according to Hardy-
Weinberg equilibrium, by 2 test. Significant differences in fre-
quencies among the three groups were calculated by 2 (by 3x3, 
3x2 and 2x2 tables, where appropriate). Furthermore, Odds Ratios 
(OR) with 95% Confidence Intervals (CI) and their significance 
were calculated.  
RESULTS  
 Tables 2 and 3 show the genotype distributions, allele fre-
quencies and the OR (95% CI) values of the TLR4 and TLR2 gene 
SNPs analysed in this study. Both the genotypes and the alleles of 
+896A/G TLR4 SNP were significantly differently distributed 
among the three groups (p=0.006 and p=0.001, respectively; Tables 
2 and 3). 
 In particular, a significant difference was observed comparing 
the genotype distributions and allele frequencies of this SNP in 
patients and centenarians (p=0.002 and p=0.0008, respectively; 
OR=16.8 (2.1-129.6; p=0.0008) (Tables 2 and 3). No significant 
differences were instead detected in the genotype distributions and 
allele frequencies of this SNP between patients and age-matched 
controls (Tables 2 and 3). In contrast, no significant differences 
were detected in the genotype distributions and allele frequencies of 
+1196C/T TLR4 SNP (Tables 2 and 3).  
 Analyzing the data of +2408G/A TLR2 SNP among the three 
cohorts, a significantly different distribution was revealed of both 
the genotypes and the alleles (p=0.0007 and p=0.0003, respec-
tively) (Tables 2 and 3). In particular, a significant difference was 
obtained comparing patients and centenarians (p=0.004 and 
p=0.002 respectively; OR=8.3 (1.8-37.2) p=0.0027), while no 
significant differences were detected between patients and age-
matched controls (Tables 2 and 3). We did not observe any 
significant difference for both genotype distributions and allele 
frequencies of the +2029C/T TLR2 SNP (Tables 2 and 3).   
 Tables 4 and 5 illustrate the genotype distributions, allele fre-
quencies and the OR (95% CI) values of -765G/C PTGS2 and -
1708G/A 5-Lo SNPs in three groups enrolled in the study. Both the 
genotypes and the alleles of -765G/C PTGS2 SNP were differently 
distributed among the three groups (p=0.01 and p=0.05, respec-
tively) (Tables 4 and 5). In particular, comparing the genotype 
distributions and the allele frequencies of this SNP of patients and 
centenarians, we observed a significant difference (p=0.03 and p= 
0.01, respectively; OR=2.1 (1.1-3.9 p=0.01) (Tables 4 and 5). In 
contrast, no significant differences were detected in the genotype 
distributions and allele frequencies of this SNP between patients 
and age-matched controls (Tables 4 and 5). Concerning the -
1708G/A5-Lo SNP, both the genotypes and the alleles were 
differently distributed among the three groups (p=0.0004 and 
p=0.0007, respectively) (see Tables 4 and 5). In particular, there 
was a significant difference in the genotype distributions and the 
allele frequencies of this SNP between patients and centenarians 
(p=0.008 and respectively p =0.0005; OR=5.17(2-13.3; p=0.0005) 
and between patients and controls (p=0.003 and p=0.005 
respectively; 2.4(1.3-4.5; p=0.005) (Tables 4 and 5).  
 In summary, these pro-inflammatory alleles were overrepre-
sented in patients compared to healthy men and underrepresented in 
centenarians compared to younger healthy controls.  
 To identify a pro-inflammatory genetic risk profile, we 
evaluated the frequency of “+896A+TLR4/+2408G+TLR2/+ 
2029C+TLR2/-765G+PTGS2/-1708A+5-Lo“ high pro-inflam-
matory“ genotype among the three cohorts. By comparing it with 
frequency of all other combinations, we observed that this “high 
responder” genotype was differently distributed among the three 
groups (p=0.002), in particular between PC patients and cente-
narians (36% vs. 11%, p=0.002; OR=4.59 (1.6-12.8), p=0.004) (see 
Table 6). 
DISCUSSION  
 PC is the most common non-skin malignant cancer in Western 
male populations. Its incidence increases rapidly in men over 50 
years of age [2]. The development of PC is based on the interaction 
between genetic factors and the host exposure to environmental 
factors, such as infectious agents, dietary carcinogens and hormonal 
imbalances [6,18-22]. In this complex situation, chronic inflam-
mation seems to play a key role. The chronically altered prostatic 
milieu is characterized by the activation of signaling pathways that 
represent a possible link between inflammation and carcinogenesis. 
Many of these factors play a dual role in the process, promoting 
neoplastic progression but also facilitating cancer prevention [6,18-
21]. 
 To date, there are no adequate biomarkers to guide PC 
prognosis and treatment [3-5]. Several studies have focused on 
detecting candidate genes, in particular genes involved in DNA 
repair, carcinogen metabolism and inflammation [6], which are 
associated with genetic susceptibility to PC and the clinical 
outcome of this disease [10,11]. Genetic variants of these genes, 
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Table 2. Genotype Distributions of +896A/G (Asp299Gly) and +1196C/T (Thr399Ile) Polymorphisms of TLR4 Gene, and of 
+2029C/T (Arg677Trp) and +2408 G/A (Arg753Gln) Polymorphisms of TLR2 Gene in 50 PC Patients, 125 Age-Matched 
Controls and 55 Centenarians from Sicily  
SNPs  Genotypes 
 
PC  
 
 
N                  % 
Age-Matched  
Controls  
 
N               % 
Centenarians  
   
 
N                % 
P1
a
  
 
 
(3x3 table) 
P2
b 
 
 
(3x2 table) 
P3
c
 
 
 
(3x2 table) 
+896A/G-TLR4  A/A 49                98 111         88.8 41                75 
 A/G  1                  2 13           10.4 12                21 
 G/G  0                  0  1              0.8   2                   4 
 
0.006* 
 
 
NS 
  
0.002** 
+1196C/T-TLR4 C/C 48                96 118            94 49                89 
 C/T  2                   4   7                6  5                   9 
 T/T  0                   0   0                0 1                   2 
 
NS 
 
 
NS 
 
NS 
+2029C/T TLR2 CC 45               90 120            96 47                85 
 CT  5                10    5               4  7                 12 
 TT  0                  0    0               0  1                   3 
 
NS 
 
 
NS  
 
NS 
+2408 G/A TLR2 GG 49                98  115             92 42                76 
 GA  1                  2  10               8 10                18 
 AA  0                   0   0                0  3                  6 
 
0.0007§ 
 
 
NS 
 
0.004§§ 
 
All genotypes were in Hardy-Weinberg equilibrium. *Significant differences by 2 test in genotype distribution of +896 A/G TLR4 SNP among the three groups were found. **A 
significant p value was also observed between patients and centenarians, analyzing by 2 test the genotype distribution of this SNP.  §The genotype distributions of +2408G/A TLR2 
SNP were significantly distributed among three groups, and §§between patients and centenarians.   
P1a = significance values calculated by 2 test , analyzing the data of these SNPs among the three groups  
P2b = significance values calculated by 2 test, analyzing the data of these SNPs between patients and age-matched controls  
P3c  = significance values calculated by 2 test, analyzing the data of these SNPs between patients and centenarians 
 
Table 3. Allele Frequencies of +896A/G (Asp299Gly) and +1196C/T (Thr399Ile) Polymorphisms of TLR4 Gene, and of +2029C/T 
(Arg677Trp) and +2408 G/A (Arg753Gln) Polymorphisms of TLR2 Gene in 50 PC Patients, 125 Age-Matched Controls and 
55 Centenarians from Sicily. (2x2 Comparisons Between the Different Groups with Odd Ratio (OR) and 95% Confidence 
Interval) 
SNPs  Alleles 
 
PC  
 
 
N         % 
Age-Matched 
 Controls  
 
N            % 
Centenarians  
   
 
N              % 
P1
a
  
 
 
(3x3 table) 
P2
b 
 
 
(3x2 table) 
P3
c
 
 
 
(3x2 table) 
OR   (95% CI) 
 
+896A/G 
TLR4  
+896A 99       99 235        94 94           85 
 +896G  1         1  15           6 16           15 
 
0.001* 
 
 
 
 
 
NS 
  
0.0008 ** 
 
6.3 (0.8-48.5; p=0.08)a 
 
2.6 (1.2-5.6; p=0.01)b 
 
16.8(2.1129.6;p=0.0008)c 
+1196C/T 
TLR4 
+1196C 98       98 243        97 103         94 
 +1196T   2         2   7            3    7             6 
 
NS 
 
 
NS 
 
NS 
_ 
_ 
_ 
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(Table 3) Contd…. 
 
SNPs  Alleles 
 
PC  
 
 
N         % 
Age-Matched  
Controls  
 
N            % 
Centenarians  
 
   
N              % 
P1
a
  
 
 
(3x3 table) 
P2
b 
 
 
(3x2 table) 
P3
c
 
 
 
(3x2 table) 
OR   (95% CI) 
 
+2029C/T TLR2 +2029C 95       95 245        98 101          92 
 +2029T  5          5   5            2   9              8     
 
NS 
 
 
 
 
NS 
 
NS 
_ 
 
_ 
 
_ 
+2408G/ATLR2 +2408G 98       98 240        96 94            85     
 +2408A  2          2  10           4 16            15 
 
 
 
0.0003§ 
 
 
 
 
NS 
 
0.002§§ 
 
2(0.4-9.4; p=0.5)a 
 
4(1.7-9.3; p=0.0008)b 
 
8.3(1.8-37.2; p=0.0027)c 
*A significant different frequency of this SNP among three groups and **in PC patients respect to centenarians was observed. §Besides, the allele frequencies of +2408G/A TLR2 SNP 
were found significantly distributed among three cohorts  and §§between patients and centenarians. 
P1a = significance values calculated by 2 test, analyzing the data of these SNPs among the three groups  
P2b = significance values calculated by 2 test, analyzing the data of these SNPs between patients and age-matched controls  
P3c = significance values calculated by 2 test (3x2 table), analyzing the data of these SNPs between patients and centenarians. 
In the last column we reported the OR values calculated for higher frequent alleles in PC patients vs. age-matched controlsa , age-matched controls vs. centenariansb; PC patients vs. 
centenarians c 
 
Table 4. Genotype Distributions of -765 G/C Polymorphism of PTGS2 Gene and of -1708 G/A Polymorphism of 5-LO Gene in 50 
PC Patients, 125 Age-Matched Controls and 55 Centenarians from Sicily  
SNPs  Genotypes 
 
PC  
 
 
N                 % 
Age-Matched  
Controls  
 
N               % 
Centenarians  
   
 
N                  % 
P1
a
  
 
 
(3x3 table) 
P2
b 
 
 
(3x2 table) 
P3
c
 
 
 
(3x2 table) 
-765G/C PTGS2 GG 31                62 65             52 27               49 
 GC 15                30 46              37 13                24 
 CC  4                  8 14              11 15                27 
 
0.01* 
 
 
 
 
 
NS 
 
 
  
0.03** 
 
-1708G/A5-Lo GG 30               60 98              78 49                89 
 GA 17                34 27              22  6                 11 
 AA  3                   6 0                 0  0                   0 
 
0.0004§ 
 
 
 
0.003§§ 
 
 
0.008§§§ 
 
All genotypes were in Hardy-Weinberg equilibrium. *Significant differences by 2 test in genotype distribution of -765G/C PTGS2 SNP among the three groups were found. **A 
significant p value was also observed between patients and centenarians, analyzing by 2 test the genotype distribution of this SNP. §The genotype distributions of -1708G/A5-Lo 
SNP were significantly distributed among three groups, and §§§between patients and centenarians and  §§between patients and age-matched controls.  
P1a = significance values calculated by 2 test, analyzing the data of these SNPs among the three groups  
P2b = significance values calculated by 2 test, analyzing the data of these SNPs between patients and age-matched controls  
P3c  = significance values  calculated by 2 test, analyzing the data of these SNPs between patients and centenarians 
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Table 5. Allele Frequencies of -765 G/C Polymorphism of PTGS2 Gene and of -1708 G/A Polymorphism of 5-LO Gene in 50 PC 
Patients, 125 Age-Matched Controls and 55 Centenarians from Sicily. 2x2 Comparisons Between the Different Groups with 
Odd Ratio (OR) and 95% Confidence Interval 
SNPs  Alleles 
 
PC  
 
 
N         % 
Age-matched  
Controls  
 
N             % 
Centenarians  
   
   
N               % 
P1
a
  
 
 
(3x3 table) 
P2
b 
 
 
(3x2 table) 
P3
c
 
 
 
(3x2 table) 
OR   (95% CI) 
 
-765G/C 
PTGS2 
-765G 77       77 176         70 67           61 
 
 
 
 -765C 23       23 74           30 43           39 
 
0.05* 
 
 
 
 
 
 
NS  
  
0.01** 
1.4(0.8-2.4; p=0.2)a 
 
 
1.5(0.9-2.4; p=0.09)b 
 
 
2.1 (1.1-3.9; p=0.01) c 
-1708G/A5-
Lo 
-1708G 77       77 
 
 
223         89 104          95 
 
 
 
 -1708A 23       23  27          11   6             5 
 
 
 
 
0.0007§ 
 
   
 0.005§§ 
 
 
0.0005§§§ 
 
 
 
2.4(1.3-4.5; p=0.005)a 
 
 
2.09(0.8-5.2; p=0.1) b 
 
 
5.17(2-13.3;p=0.0005)c 
*An over-expression of -765G pro-inflammatory allele among the three groups and **in PC patients respect to centenarians was observed. §Besides, the allele frequencies of -
1708G/A5-Lo SNP were found significantly differently distributed among three cohorts, and §§between patients and age-matched controls and §§§between patients and centenarians.  
P1a = significance values calculated by 2 test, analyzing the data of these SNPs among the three groups  
P2b = significance values calculated by 2 test, analyzing the data of these SNPs between patients and age-matched controls  
P3c  = significance values calculated by 2 test, analyzing the data of these SNPs between patients and centenarians  
In the last column we reported the OR values calculated for higher frequent alleles in PC patients vs. age-matched controlsa , age-matched controls vs. centenariansb; PC patients vs. 
centenarians c 
 
Table 6. The Frequency of +896A+TLR4/+2408G+TLR2/+2029C+TLR2/-765G+PTGS2/-1708A+5-Lo“High Responder“(Pro-
Inflammatory) Genotype Among the Three Cohorts 
 +896A+TLR4/+1196C+TLR4/+2408G+TLR2/+2029C+TLR2/-765G+PTGS2/1708A+5Lo 
“high-responder“ (pro-inflammatory) Genotype 
Other Genotypes 
Patients     
(N=50)        
18 32 
Age-matched Controls  
(N=125) 
44 81 
Centenarians  
(N=55) 
6 49* 
* Significant differences by 2 test (3x3 table) in this genotype frequency among the three groups and between patients and centenarians (p= 0.002) were observed.  
 
primarily SNPs, may modulate and be associated with increased 
chronic inflammation and carcinogenesis of the prostate gland. In 
addition, they may operate in combination to create a “risk profile” 
[6]. It is also generally believed that such SNPs can modify the 
effectiveness of therapies of various age-related diseases, including 
PC. Accordingly, SNPs associated with polygenic traits represent a 
major goal of many pharmaceutical companies to discover novel 
therapeutic molecular targets [23,24]. 
 Based on the above considerations, we have analyzed the role 
in PC of six SNPs of the TLR4, TLR2, PTGS2 and 5-Lo genes, 
encoding molecules primarily implicated in innate immunity and 
inflammatory response. Our results indicate that pro-inflammatory 
SNPs of some of these genes are significantly associated with PC. 
Furthermore, we identified a risk profile in PC patients compared to 
centenarians, used in our study as an additional control group of 
“exceptional individuals” able to avoid major common age-related 
diseases, including cancer [12-14]. As we have previously demons-
trated that alleles associated with age-related diseases are not 
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included in the genetic profile favoring longevity [25,26], a genetic 
background promoting pro-inflammatory responses may play 
opposite roles in age-related diseases, including PC, and in 
longevity.  
 On the basis of data reported herein, some inference on their 
translational impact can be drawn. The presence of “high-risk” 
alleles of the PTGS2 and the 5-LO genes may suggest the possi-
bility of developing preventive measures using specific inhibitors of 
eicosanoids and/or their enzymes. For people who do not respond to 
(or comply with) NSAID therapy, other more sophisticated 
preventive approaches may be possible [6], including the use of 
agonists of TLR receptors in subjects who are carriers of +896A/G 
TLR4 and +2408 G/A TLR2 SNPs. The aim of such an approach 
would be to block the TLR-NF-B signaling pathway required for 
induction of inflammatory responses and the release of pro-
inflammatory mediators. This approach might reduce the risk of PC 
development [6,27]. Another possible therapeutic intervention in 
subjects with pro-inflammatory alleles of TLR4 and TLR2 genes 
might be antibody-mediated stimulation of TAM receptors involved 
in the inhibition of the inflammatory response. The sequential 
induction of this pathway, and its integration with upstream TLR 
and cytokine signaling networks, may limit the inflammatory 
response and maintain innate immune system homeostasis. A better 
understanding of the regulatory mechanisms of this cascade may 
have important implications for therapeutic intervention in human 
immune disorders [28,29]. 
 Although our study presents some limitations primarily related 
to the relatively small number of patients and controls, it compares 
subjects belonging to a very homogeneous population from Sicily. 
Thus, our data are likely to be at least as reliable as those from 
studies performed on larger cohorts of patients from Northern 
Europe or the United States, which are ethnically matched to 
Caucasians in general. Conversely, as discussed by Caruso et al. 
[6], the use of centenarians as “super-controls” might enhance the 
possibility of identifying the genetic profile characterizing 
susceptibility and/or resistance to PC. It may be argued that a 
Bonferroni-type adjustment should be performed to correct for 
testing multiple polymorphisms. However, we feel that this 
correction is too stringent and has the potential to ignore important 
observations [30]. In any case, further investigations on larger 
homogenous populations are needed to corroborate the present 
evidence.  
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ABBREVIATIONS  
ARMS-PCR = Allele Refractory Mutation System-PCR  
CI = Confidence Interval 
COX-2 = Cyclo-Oxygenase-2 
OR = ODD Ratio 
5-Lo = 5-Lypoxygenase  
PC = Prostate Cancer 
PSA = Serum Prostate-specific Antigen 
PTGS2 = Prostaglandin E Synthase 2 gene of 
cyclooxygenase-2  
RFLP-PCR = Restriction Fragment Length Polymorphism-
PCR 
SNP = Single Nucleotide Polymorphism  
TAM = TAM receptor 
TLR4 = Toll-Like Receptor-4 
TLR2 = Toll-Like Receptor-2 
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